The immunopathology of intraocular tumour rejection was studied using two trans plantable tumours in mice. UV5C25 fibrosarcoma and P91 mastocytoma express tumour specific antigens that elicit strong systemic T cell-mediated immune responses following intracameral transplantation. Although both tumours under went immunological rejection, the immunopathological sequelae of tumour rejec tion differed markedly. P91 tumour rejection was accompanied by bulk ischaemic necrosis, microvascular damage, and extensive damage to innocent bystander cells. The eye has been likened to an immunological microcosm in which virtually all forms of immunological events can take place, and occasionally do so with disastrous con sequences.1 Indeed, inflammatory diseases are important causes of blindness. The possi bility that inflammatory eye diseases, such as uveitis, were immune-mediated was proposed over 80 years ago by Elschnig. 2 Subsequently, literally scores of studies have produced com pelling evidence that at least some forms of idiopathic uveitis are immune-mediated.
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Recent advances in the field of tumour immunology offer glimmers of optimism for the eventual implementation of immuno therapy for a variety of neoplasms, especially malignant melanoma. Impressive results with the use of tumour infiltrating lymphocytes (TIL) in the treatment of metastatic cutane ous melanoma and the recent NIH approval to implement gene therapy into current pro tocols for TIL immunotherapy are a testa ment to the rapid progress in this field. 3 The swift development and application of novel immunotherapeutic procedures underscore the urgency for understanding the immuno biology of intraocular tumours. Unlike other anatomical regions, the intraocular milieu possesses unique biological and immunolog ical characteristics that can present important complications for implementing immuno therapeutic modalities. Our ongoing studies, summarised here, have attempted to charac terise the immunobiology of intraocular tumour rejection.
It is clear that protective immune responses that shield the eye from infectious diseases can unwittingly produce deleterious immune mediated damage to innocent bystander cells within the eye. Historically, the basic immune mechanisms of tissue damage have been cate gorised into four basic types: (i) type I = anaphylactic; (ii) type II = cytotoxic; (iii) type III = immune complexes; and (iv) cell-mediated.
The first three categories of immune mediated damage involve antibody. Type I hypersensitivity involves the degranulation of mast cells by antigen specific , IgE antibodies. Classical allergic or immediate hypersensitiv ity responses are loosely categorised as a form of immune mediated tissue damage. Type II hypersensitivity reactions produce direct tis sue damage by cytolytic antibodies and the fixation of complement. Type III hypersensi tivity injury occurs indirectly. Antigen-anti body complexes activate the complement cascade which in turn culminates in a con stellation of events including the recruitment of activated neutrophils, deposition of fibrin, release of leukocytic lysosomal enzymes, and increased vascular permeability. Type IV hypersensitivity produces tissue destruction by one of two independent T cell-mediated processes. Cytotoxic T lymphocytes (CTL) can produce damage by direct cytolysis of the target cell. This form of immune reactivity is crucial in the elimination of infectious virus. Virally infected cells are recognised by virus specific CTL that directly lyse the infected host cell via recognition of the viral antigens displayed on the cell membrane of the infected host cell. Cytolysis requires the recognition of both the relevant viral antigen and the presence of the host's unique class I major histocompatibility complex (MHC) antigens concomitantly displayed in associ ation with the viral antigens. In order to study immunologic regulation within the eye, we have relied heavily on murine models which permit immunologic and immunogenetic analyses not possible in any other laboratory animal. During the course of these studies it has become apparent that two distinct categories of spontaneous tumour rejection are distinguishable. 4-l\ The first pattern culminates in ischaemic necrosis en masse and the complete atrophy of the affected eye. This model involves the use of a highly immunogenic mastocytoma (P91) which expresses tumour specific antigens that are readily recognised by the syngeneic DBA/2 mouse host. was followed by necrosis of the tumour en masse. Importantly, there was no evidence of piecemeal necrosis or direct cell-to-cell con tact between host inflammatory cells and the tumour cells. Tumour resolution was com plete by day 28 but resulted in extensive path ological sequelae to normal host tissues. Ischaemic necrosis resulted in scarring of the iris, cataract formation, and granulation scar tissue formation which in turn caused retinal detachment and ultimately, complete atrophy of the eye. Thus, the histopathological fea tures of P91 tumour rejection were consistent with a DTH process based on: (i) microvascular damage; (ii) ischaemic bulk necrosis; (iii) significant damage to innocent bystan der cells; (iv) the conspicuous absence of piecemeal necrosis of individual tumour cells. The sudden onset and completion of tumour resolution could not be regarded as simply a case of the tumour outgrowing its blood supply since the same tumours grew progressively in T cell-deficient nude mice and sublethally irradiated ( = leukopenic) euthymic DBA/2 mice ( Figure 1) . Thus, the ischaemic necrotic pattern of tumour rejec tion was T cell-dependent and radiosensitive.
The potential T cell-dependent, radiosensi tive effector mechanisms that might produce tumour rejection include: CTL, DTH, or anti body. Additional experiments considered each of these effector modalities.
The possible role of antibody in ischaemic tumour rejection was evaluated in several experiments. If antibodies were involved, it should be possible to reproduce these seque lae by passively transferring hyperimmune serum to immunologically naive recipients. Accordingly, panels of sublethally irradiated DBA/2 mice and T cell-deficient nude BALB/c mice received multiple injections of hyperimmune serum from hosts who had rejected their intraocular P91 tumours.7 Even though the recipients received large quanti ties of hyperimmune serum, tumour growth was not arrested nor was there evidence of ischaemic necrosis of the affected eye (Table  I) .
Additional investigations considered the hypothesis that the complement cascade was involved in the ischaemic necrotic pattern of intraocular tumour rejection. This was exam ined by using the BI0.D20Sn mouse strain which is incapable of producing the C5 com ponent of complement.9 Tumour rejection in this complement-deficient mouse strain was compared with that occurring in the BlO.D2nSn counterpart which possesses normal complement activity. The results showed that tumour rejection was virtually identical in both mouse strains and culmi nated in ischaemic necrosis of the affected eye and tumour (Table II) .
The aforementioned results indicated that antibody alone could not promote either tumour rejection or ischaemic necrosis of the tumour-containing eye. Likewise, the absen.ce of complement did not affect the ischaemic necrotic pattern of tumour rejec tion. Additional experiments further sup ported the hypothesis that antibody was not involved in this form of immune-mediated ischaemic necrosis. These experiments were based on our previous observation that sple nectomised mice fail to produce detectable antibody responses to antigens presented intracamerally. Accordingly, panels of sple nectomised and normal DBA/2 mice received intracameral inoculations of P91 tumour cells.
As expected, anti-tumour antibodies could be detected in only two of the 11 splenectomised hosts, yet ischaemic tumour rejection occurred in all hosts and resulted in phthisis of all of the eyes examined (Table II) .
It is well known that tumour necrosis factor (TNF) can produce haemorrhagic necrosis of The results described above indicate that antibody was neither directly or indirectly involved in immune-med"iated ischaemic nec rosis of intraocular tumours. Recent studies in our laboratory have provided compelling evi dence that CTL are not responsible for the observed ischaemic necrotic pattern of tumour rejection. Mice were treated system ically with anti-CD8 monoclonal antibody as a means of depleting the subpopulation of T lymphocytes that mediate classical cytotoxic T lymphocyte activity. 1O The results showed that the antibody treatment completely abol ished anti-tumour CTL activity (data not shown), yet the characteristic pattern and tempo of ischaemic necrotic tumour rejection was unaffected (Fig. 1) .
The most plausible explanation to account for the ischaemic necrotic pattern of tumour rejection involves DTH-mediated processes. The weight of evidence indicates that rejec tion, although T-cell-dependent and radiosen sitive, was not mediated by either antibody, TNF, or CTL. By the process of elimination, we are left to conclude that DTH is intimately involved in this process. The observed micro vascular injury, ischaemic necrosis en masse, and the heavy burden of innocent bystander damage to normal ocular tissues are findings reminiscent of the lesions produced by severe DTH reactions in the skinll,12 and in rejecting tumours, 1 3 -15 Although the P91 tumour is not a model of human intraocular tumours, its unique pat tern of rejection bears a curious similarity to the behaviour of retinoblastoma which is known occasionally to undergo spontaneous resolution,16,17 Some investigators have sug gested that the spontaneous resolution of retinoblastoma is due to immunologic rejec tion.Is Moreover, reports of intraocular inflammation preceding the spontaneous res olution of retinoblastomas19 and the demon stration of tumour-specific antigens on several retinoblastoma cell lines20 suggest that the immune system may indeed recognise retino blastomas and mediate their destruction. It bears noting that spontaneous resolution of retinoblastomas often culminates in phthisis bulbi,I6 a condition not unlike the ischaemic necrotic pattern of intraocular P91 tumour rejection,
Immunological Rejection of Intraocular Tumours: Piecemeal Necrotic Pattern
In sharp contrast to the previously described pattern of tumour rejection is a second form of tumour resolution which culminates in the complete erradication of neoplasm without disturbing the anatomic integrity of the affected eye. The transplantable ultraviolet 10 Tumour rejection occurred by an 'ischaemic necrotic ' pattern that was clinically indistinguishab le from previous experiments . U radiation (UVR) induced fibrosarcoma, UV5C25 is a prototype of this form of intra ocular tumour rejection.5.8 Intraocular UV5C25 tumours undergo a prolonged form of immunologic rejection in the eyes of syn geneic BALB/C mice.5,s Histopathological analysis of the resolving tumours revealed an impressive lymphocytic infiltrate accom panied by piecemeal necrosis of individual tumour cells. Direct binding of lymphocytes to individual tumour cells was a common fea ture of the resolving intraocular UV5C25 tumours and strongly suggested that tumour rejection was mediated by direct cytolysis by tumour-specific CTL. Immunological analy ses were conducted to test this hypothesis.
Our approach to these studies was crudely patterned after 'Koch's Postulates' in which we sought to: (i) isolate tumour-specific CTL from resolving tumours; (ii) culture the isolated, tumour-specific CTL in vitro: (iii) demonstrate their expression of surface markers characteristic of CTL; (iv) demonstrate cytolytic antitumour activ ity in vitro; (v) transfer the antitumour effect to naive recipients. Each of these criteria has been confirmed and the results have been reported else where.5.8 Fluorescein activated cell sorter (FACS) analysis of the tumour infiltrating lymphocyte (TIL) population indicated that the both CD4+ and CD8+ T cells were pres ent in the resolving tumour mass (Fig. 3) .
However, in vitro functional assays indicated that the TIL displayed impressive direct cyto toxicity for UV5C25 tumours. to prevent rejection by eliminating CTL. This hypothesis was confirmed in recent experi ments in which CTL populations were elim inated in vivo by treating BALB/c hosts with anti-CD8 antibody. In vivo treatment with anti-CD8 antibody resulted in a profound depletion of tumour specific CTL activity (data not shown) and the progressive growth of intraocular tumours (Fig. 4) . Histological examination of the resolving intraocular tumours revealed an impressive absence of mononuclear inflammatory cells (data not shown). The eyes of anti-CD8 treated euth ymic mice were histologically and grossly indistinguishable from T cell-deficient nude mice8-in both categories of mice, mono nuclear inflammatory cells were not detected at any time point examined. Thus, the weight of evidence favours the hypotliesis that the piecemeal necrotic pattern of intraocular tumour rejection is mediated by CTL and that the DTH effector mechanism is excluded.
Regulation of Immunologic Effector Mechanisms in the Eye
The experimental findings summarised here underscore the complexity of intraocular immune regulation. The tumour models util ised for these studies were not intended to serve as counterparts to human uveal melan oma or retinoblastoma. Rather, they were employed as tools better to understand the immunobiology and immunopathology of intraocular tumours. Although both intra ocular tumours induced potent tumour-speci- fic CTL and DTH responses, only one immune mechanism was actively engaged within the intraocular milieu.
In the ischaemic necrotic pattern of tumour rejection, DTH effector mechanisms pre vailed. The initiation of the DTH reaction in oculi was antigen specific; however, the effec tor arm was non-specific. The most likely sce nario is that activated DTH effector T cell population elaborated a constellation of cyto kines including interferon gamma and IL-2 which in turn recruited, activated, and sus tained second level effector cells (e.g. macro phages and neutrophils) which produced indiscriminant tissue damage including fibrin deposition, thrombus formation, infarction, and bulk ischaemic necrosis. Although the initiation of this T cell-dependent mechanism possessed exquisite antigen specificity, the execution of this process was antigenically indiscriminant. Although the immune system suceeded in ridding the eye of the life threatening neoplasm, a heavy toll was paid in the irreparable damage to juxtaposed normal ocular tissues.
The piecemeal necrotic pattern of tumour rejection exemplified the teleological ideals of immunological effector mechanisms-that is, elimination of a neoplasm without injuring delicate host tissues which are incapable of regeneration. Unlike DTH effector mechan isms, cytolysis by CTL occurred with exqui site antigen specificity during both the induction and execution of the antitumour response. Tumour cells were categorically eliminated while neighbouring normal cells were spared.
Gaining a clear understanding of these immunoregulatory phenomena may permit the implementation of rapidly emerging, novel immunotherapeutic strategies for treat ing intraocular neoplasms without jeopardis ing the anatomical integrity of the eye. 
